Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Antiphospholipid Syndrome
•
Systemic lupus erythematosus
•
Benign Hematology
•
Anticoagulation
•
Hospital Medicine
How would you approach a patient with SLE and catastrophic antiphospholipid antibody system that has not responded to heparin, steroids, and PLEX?
How do you decide amongst other therapies such as eculizumab, rituximab, cyclophosphamide, IVIg?
Related Questions
How would you counsel a woman with a strong family history of thrombosis about oral contraceptives?
Do you avoid JAK inhibitors in patients with antiphospholipid antibodies and/or lupus anticoagulant given the potential risk of increased thromboembolic events with use of JAKi?
What are some practical tips for tacrolimus management/monitoring in SLE nephritis?
What do you feel are the potential barriers to widespread use of obinutuzumab in proliferative lupus nephritis?
What factors drive you to prioritize treatments that inhibit T cells vs B cell depletion when choosing therapies for patients with refractory SLE?
How do you approach inpatient DVT prophylaxis in patients already on low dose rivaroxaban 2.5 mg BID for PAD?
What additional workup would you perform to evaluate a new onset of spontaneous hemarthrosis?
Are there instances when you consider rituximab first line in a patient with class V LN?
Do you favor obinutuzumab over voclosporin for patients with lupus nephritis and significant proteinuria and a history of non-adherence to medications?
How do you taper corticotropin injections (Acthar) in patients with rheumatologic disease?